Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

Delayed Quote. Delayed  - 07/22 05:35:12 pm
97.46 EUR   +0.15%
07/18 MERCK KGAA : Darmstadt, Germany Receives European Medicines Agency A..
07/13 MERCK KGAA : Advances Water Purification Systems with New High-Throu..
07/12 MERCK KGAA : Expands Excipients Portfolio, Adding Polymers for Susta..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Merck KGaA : Effect Pigments for Architecture: Merck Exhibits at the Middle East Coatings Show 2012

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/05/2012 | 10:24am CEST

Darmstadt/Germany, March 5, 2012 - Merck will be presenting its effect pigments for architecture at the Middle East Coatings Show in Dubai from March 12 to 14, 2012. This exhibition is the most important platform for the coatings sector in the Middle East and the Gulf region. The focus of the exhibition will be on architectural applications, which have been seeing rapid growth in the region for the past several years. The trend toward gold and silver shades, which can currently be seen in lifestyle products and interior designs, is also being reflected in architecture.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
07/18 MERCK KGAA : Darmstadt, Germany Receives European Medicines Agency Acceptance fo..
07/14 MERCK KGAA : EMD Serono Commits EUR1.5 million to the Grant for Fertility Innova..
07/14 MERCK KGAA : Recent Findings from Merck KGaA Provides New Insights into Fenofibr..
07/13 MERCK KGAA : Advances Water Purification Systems with New High-Throughput Line
07/12 MERCK KGAA : Expands Excipients Portfolio, Adding Polymers for Sustained Release..
07/11 MERCK : and University of Nairobi to Start Medical Oncology Fellowship Program
07/10 MERCK : and University of Nairobi to Start Medical Oncology Fellowship Program M..
07/07 MERCK KGAA : MilliporeSigma to Develop Next-Generation Purification Processes wi..
07/07 Merck KGaA, Darmstadt, Germany Welcomes ZEISS and Hamilton Thorne as New Memb..
07/06 MERCK KGAA : Phase III trial to evaluate avelumab as first-line treatment in ova..
More news
Sector news : Specialty & Advanced Pharmaceuticals
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJBAYER : 2Q 2016 -- Forecast
07/22DJMonsanto Wins EU Nod for New Biotech Soybeans
07/21DJBIOGEN : Announces CEO Search, Lifts Guidance--2nd Update
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
07/18 Merck's marketing application for Cladribine tablets accepted for review in E..
07/06 Late-stage study commences assessing Merck KGaA and Pfizer's avelumab + chemo..
07/05 OneCrinone reproductive treatment approved in Japan
06/24 Sector Licks Its Brexit Wounds
06/24 Eylea Combinations And Array's Play For Melanoma
Advertisement
Financials (€)
Sales 2016 15 084 M
EBIT 2016 3 244 M
Net income 2016 1 632 M
Debt 2016 10 889 M
Yield 2016 1,24%
P/E ratio 2016 24,87
P/E ratio 2017 23,03
EV / Sales 2016 1,56x
EV / Sales 2017 1,40x
Capitalization 12 596 M
More Financials
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 97,9 €
Spread / Average Target 0,41%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stefan Oschmann Chief Executive Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Laszlo Radvanyi Senior Vice President & Head-Research
Crocifissa Attardo Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA8.64%13 824
ABBVIE INC7.71%103 204
BIOGEN INC-6.06%63 059
KYOWA HAKKO KIRIN CO L..-0.10%10 328
JAZZ PHARMACEUTICALS P..1.00%8 587
MALLINCKRODT PLC-10.91%7 269
More Results